1. |
Abe E, Marians RC, Yu W, et al. TSH is a negative regulator of skeletal remodeling. Cell, 2003, 115(2): 151-162.
|
2. |
Stathatos N, Wartofsky L. Perioperative management of patients with hypothyroidism. Endocrinol Metab Clin North Am, 2003, 32(2): 503-518.
|
3. |
Mariotti S, Cambuli V. Cardiovascular risk in elderly hypothyroid patients. Thyroid, 2007, 17(11): 1067-1073.
|
4. |
De Vito P, Incerpi S, Pedersen JZ, et al. Thyroid hormones as modulators of immune activities at the cellular level. Thyroid, 2011, 21(8): 879-890.
|
5. |
De Vito P, Balducci V, Leone S, et al. Nongenomic effects of thyroid hormones on the immune system cells: New targets, old players. Steroids, 2012, 77(10): 988-995.
|
6. |
Tan TL, Rajeswaran H, Haddad S, et al. Increased risk of periprosthetic joint infections in patients with hypothyroidism undergoing total joint arthroplasty. J Arthroplasty, 2016, 31(4): 868-871.
|
7. |
Buller LT, Rosas S, Sabeh KG, et al. Hypothyroidism increases 90-day complications and costs following primary total knee arthroplasty. J Arthroplasty, 2018, 33(4): 1003-1007.
|
8. |
中华医学会内分泌学分会《中国甲状腺疾病诊治指南》编写组. 甲状腺疾病诊治指南——甲状腺功能减退症. 中华内科杂志, 2007, 46(11): 967-971.
|
9. |
周程沛, 何军慧, 周宗科, 等. 甲状腺功能减退症患者髋或膝关节置换术围手术期的处理. 华西医学, 2012, 27(5): 665-669.
|
10. |
Ding ZC, Xu B, Liang ZM, et al. Limited influence of comorbidities on length of stay after total hip arthroplasty: experience of enhanced recovery after surgery. Orthop Surg, 2020, 12(1): 153-161.
|
11. |
Gross JB. Estimating allowable blood loss: corrected for dilution. Anesthesiology, 1983, 58(3): 277-280.
|
12. |
Della Valle C, Parvizi J, Bauer TW, et al. American academy of orthopaedic surgeons clinical practice guideline on: the diagnosis of periprosthetic joint infections of the hip and knee. J Bone Joint Surg (Am), 2011, 93(14): 1355-1357.
|
13. |
Elbers LPB, Fliers E, Cannegieter SC. The influence of thyroid function on the coagulation system and its clinical consequences. J Thromb Haemost, 2018, 16(4): 634-645.
|
14. |
Michiels JJ, Schroyens W, Berneman Z, et al. Acquired von Willebrand syndrome type 1 in hypothyroidism reversal after treatment with thyroxine. Clin Appl Thromb Hemost, 2001, 7(2): 113-115.
|
15. |
Marongiu F, Cauli C, Mariotti S. Thyroid, hemostasis and thrombosis. J Endocrinol Invest, 2004, 27(11): 1065-1071.
|
16. |
Hoylaerts M, Lijnen HR, Collen D. Studies on the mechanism of antifibrinolytic action of tranexamic acid. Biochim-Biophys Acta, 1981, 673(1): 75-85.
|
17. |
Liu X, Zhang X, Chen Y, et al. Hidden blood loss after total hip arthroplasty. J Arthroplasty, 2011, 26(7): 1100-1105.
|
18. |
Huang Z, Ma J, Shen B, et al. Combination of intravenous and topical application of tranexamic acid in primary total knee arthroplasty: a prospective randomized controlled trial. J Arthroplasty, 2014, 29(12): 2342-2346.
|
19. |
Xie J, Ma J, Yao H, et al. Multiple boluses of intravenous tranexamic acid to reduce hidden blood loss after primary total knee arthroplasty without tourniquet: a randomized clinical trial. J Arthroplasty, 2016, 31(11): 2458-2464.
|
20. |
Grunfeld R, Kunselman A, Bustillo J, et al. Wound complications in thyroxinesupplemented patients following foot and ankle surgery. Foot Ankle Int, 2011, 32(1): 38-46.
|
21. |
Bozic KJ, Lau E, Kurtz S, et al. Patient-related risk factors for postoperative mortality and periprosthetic joint infection in medicare patients undergoing TKA. Clin Orthop Relat Res, 2012, 470(1): 130-137.
|
22. |
El-Shaikh KA, Gabry MS, Othman GA. Recovery of age-dependent immunological deterioration in old mice by thyroxine treatment. J Anim Physiol Anim Nutr (Berl), 2006, 90(5-6): 244-254.
|